Results 161 to 170 of about 6,418,597 (300)

Nanoporous Carbon Coating of Separator Boosts Rate Capability of Cathodes in Lithium-Ion Batteries. [PDF]

Adv Mater
Murphy SP, Leuenberger NM, Chen S, Crooks E, Jung MS, Tchelepi H, Ji X.   +6 more
europepmc   +1 more source

Novel K₂Ti₈O₁₇ Anode via Na⁺/Al³⁺ Co-Intercalation Mechanism for Rechargeable Aqueous Al-Ion Battery with Superior Rate Capability. [PDF]

Nanomaterials (Basel), 2021
Feng Q, Liu Y, Yan J, Feng W, Ji S, Tang Y.   +5 more
europepmc   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Graphdiyne Oxide-Enabled Solid-State Proton Battery Exhibiting Superior Rate Capability. [PDF]

Angew Chem Int Ed Engl
Huang Y, Xiong Z, Liu H, Sun H, Su W, Chen Z, Zhoumei W, Liu H.   +7 more
europepmc   +1 more source

Enhancing Li-ion capacity and rate capability in cation-defective vanadium ferrite aerogels via aluminum substitution. [PDF]

RSC Adv, 2021
Chervin CN, DeBlock RH, Parker JF, Hudak BM, Skeele NL, Ko JS, Rolison DR, Long JW.   +7 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Capability Modeling: Initial Experiences

Enterprises operate in dynamically changing environments, consequently, information systems (IS) are a subject to continuous changes. The IS need to be adjusted to different customers, markets and run-time contexts affecting their design and delivery ...
Grabis, Jānis, Bravos, George, Koc, Hasan, Henkel, Martin, Gonzales, Tania, Stirna, Jānis, Jokste, Lauma   +6 more
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Suppressing Intrinsic Anti-Site Defects via Targeted Li-Occupation Unlocks Ultrahigh-Rate Capability in Vanadium-Free NASICON Cathodes. [PDF]

Adv Mater
Wu Y, Liu F, Zhang C, Guan C, Liu Y, Li H, Lin Z, Li X, Zhang J, Wang Y, Zhu Y, Li H, Ren Y, Huang H.   +13 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source